# HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

> **NCT03354390** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 17 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **BIOLOGICAL:** cell infusion

## Key facts

- **NCT ID:** NCT03354390
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-07-20
- **Primary completion:** 2023-10-31
- **Final completion:** 2029-03-03
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03354390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03354390, "HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03354390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*